Literature DB >> 32043795

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.

Hajime Uno1,2, Miki Horiguchi1, Michael J Hassett1.   

Abstract

Entities:  

Keywords:  Interpretability; Robustness; Survival data analysis; Test/estimation coherency; Treatment decision making

Mesh：

Year:  2019        PMID： 32043795      PMCID： PMC7011662          DOI： 10.1634/theoncologist.2019-0464

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  12 in total

1.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

2.  How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Authors:  Miki Horiguchi; Michael J Hassett; Hajime Uno
Journal:  Oncologist       Date:  2018-09-10

3.  Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

Authors:  Roger P A'Hern
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

4.  Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.

Authors:  Bo Huang; Pei-Fen Kuan
Journal:  Pharm Stat       Date:  2017-12-28       Impact factor: 1.894

5.  Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.

Authors:  F Liang; S Zhang; Q Wang; W Li
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

6.  The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

Authors:  Julien Péron; Pascal Roy; Brice Ozenne; Laurent Roche; Marc Buyse
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

7.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

8.  Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.

Authors:  R P A'Hern
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-09       Impact factor: 4.126

Review 9.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

10.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615
View more
  1 in total

1.  Optimal two-stage designs based on restricted mean survival time for a single-arm study.

Authors:  Guogen Shan
Journal:  Contemp Clin Trials Commun       Date:  2021-01-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.